Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Advent Life Sciences
AI-generated illustration
OrganisationGB

Advent Life Sciences

London life-sciences venture firm; co-led T-Therapeutics' $133m Series B with the British Business Bank.

Last refreshed: 14 November 2026 · Appears in 1 active topic

Key Question

Why does the British Business Bank keep backing biotech beside Advent?

Timeline for Advent Life Sciences

#17 5 Nov

Co-led T-Therapeutics' Series B

UK Startups and Innovation: T-Therapeutics raises $133m in Series B
View full timeline →

Background

Advent Life Sciences, a London venture firm that invests in drug and medical-technology companies, co-led T-Therapeutics' $133m Series B on 5 November 2026 with the British Business Bank. The Bank called it its third co-investment beside Advent.

Advent spun out of Advent Venture Partners and has offices in London, Paris and Boston. Its general partner Dominic Schmidt said T-cell engagers had succeeded in blood cancers but had been held back in solid tumours, the gap T-Therapeutics targets. It is a separate firm from the buyout group Advent International.

Common Questions
Who is Advent Life Sciences?
A London venture firm that invests in drug and medical-technology companies. It co-led T-Therapeutics' $133m Series B in November 2026.Source: BioPharm International
Is Advent Life Sciences part of Advent International?
No. Advent Life Sciences spun out of Advent Venture Partners and is a separate firm from the buyout group Advent International.Source: Advent Life Sciences
How often has the British Business Bank invested with Advent Life Sciences?
The Bank called T-Therapeutics its third co-investment beside Advent.Source: British Business Bank
Source Material

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.